References
| Author (yr) | Title | Citation | Isolate |
|---|---|---|---|
| Steegen (2022) | Minimal Cross-resistance to Tenofovir in Children and Adolescents Failing ART Makes Them Eligible for Tenofovir-Lamivudine-Dolutegravir Treatment. | Pediatr Infect Dis J | PR HIV1 group M: 650 RT HIV1 group M: 650 |